Condition: Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma · Mixed Phenotype Acute Leukemia · Sponsor: St. Jude Children's Research Hospital
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.
This description comes directly from the study's public registry record.
Seth E. Karol, MD · 888-226-4343 · referralinfo@stjude.org
Always discuss trial participation with your own doctor first.
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Our Lady of the Lakes Regional Medical Center | Baton Rouge, Louisiana, United States | Recruiting |
| Novant Health Presbyterian Hemby Children's Hospital | Charlotte, North Carolina, United States | Recruiting |
| Saint Francis Children's Hospital | Tulsa, Oklahoma, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06289673